PRESS RELEASE published on 09/14/2024 at 09:05, 2 years ago Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments Transgene and BioInvent present promising early results of oncolytic virus BT-001 in ESMO 2024, showing antitumor activity in solid tumors. BT-001 induces tumor regression and enhances T cell infiltration Transgene Oncolytic Virus BioInvent Antitumor Activity ESMO 2024
BRIEF published on 09/13/2024 at 10:37, 2 years ago Franchissement de seuil par SITAM Belgique dans TRANSGENE S.A. Droits De Vote Franchissement De Seuil Augmentation De Capital SITAM Belgique TRANSGENE S.A.
BRIEF published on 09/13/2024 at 10:37, 2 years ago Threshold crossing by SITAM Belgium in TRANSGENE SA Voting Rights Capital Increase Threshold Crossing SITAM Belgium TRANSGENE SA
PRESS RELEASE published on 09/13/2024 at 10:32, 2 years ago Franchissement de seuil Déclaration de franchissement de seuil de la société TRANSGENE S.A. par SITAM Belgique, détenant 3,65% du capital et 4,85% des droits de vote Déclaration Franchissement De Seuil AMF SITAM Belgique TRANSGENE S.A.
BRIEF published on 09/10/2024 at 07:35, 2 years ago Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation Cancer Treatment Oncology Leadership Immunotherapy Transgene
BRIEF published on 09/10/2024 at 07:35, 2 years ago Transgene nomme deux leaders chevronnés en oncologie pour piloter sa prochaine phase d'innovation Immunothérapie Direction Oncologie Traitement Du Cancer Transgene
PRESS RELEASE published on 09/10/2024 at 07:30, 2 years ago Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to drive innovation in cancer immunotherapies. Company progresses clinical pipeline with therapeutic vaccine TG4050 Innovation Oncology Clinical Pipeline Immunotherapy Transgene
BRIEF published on 08/27/2024 at 07:35, 2 years 1 month ago Transgene Publishes Preclinical Data on Oncolytic Virus TG6050 in JITC Preclinical Data Transgene Oncolytic Virus TG6050 JITC
BRIEF published on 08/27/2024 at 07:35, 2 years 1 month ago Transgene publie des données précliniques sur le virus oncolytique TG6050 au JITC Transgene Données Précliniques TG6050 JITC Virus Oncolytique
PRESS RELEASE published on 08/27/2024 at 07:30, 2 years 1 month ago Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC Transgene announces preclinical proof-of-concept data of oncolytic virus TG6050 published in JITC, showcasing tumor regression and immune remodeling capabilities without systemic toxicity. TG6050 progressing in Phase I trial for NSCLC Phase I Trial Transgene Oncolytic Virus TG6050 JITC Publication
Published on 10/03/2026 at 02:35, 1 day 20 hours ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 2 days 9 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 2 days 10 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 2 days 10 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/04/2026 at 06:05, 17 hours 7 minutes ago Blokees Debuts 90+ New Products at Wonder Festival Shanghai 2026
Published on 10/04/2026 at 05:15, 17 hours 57 minutes ago SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Published on 10/03/2026 at 15:45, 1 day 7 hours ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 23 hours ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 2 days 2 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 17:45, 2 days 5 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 2 days 5 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 2 days 5 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 2 days 5 hours ago Aéroports de Paris SA - Calendrier financier 2027